Shaily Engineering Plastics is pivoting its business toward healthcare, with GLP-1 pen injectors driving growth. While the stock has seen a massive rise since 2024, the company is betting on significant capacity expansion and new semiconductor chip tray manufacturing. Investors should note the high valuation and potential competition from oral drug therapies.
What Happened
Shaily Engineering Plastics has undergone a significant transformation, moving from a general plastic component maker to a specialized healthcare manufacturing firm. The company is now heavily focused on manufacturing pen injectors for GLP-1 drugs—a class of medications used for diabetes and weight management. This strategic pivot has resonated with the market, as the company's stock has quadrupled since April 2024. Despite a modest 8.7% year-over-year revenue growth in the fourth quarter of fiscal year 2026, the company’s focus on high-value healthcare products continues to reshape its financial profile.
The Healthcare Pivot
Healthcare has become the central pillar of Shaily Engineering’s business, now contributing nearly half of its projected revenue for fiscal year 2026. The shift is driven by the rising demand for pen-based drug delivery systems. The company benefits from high entry barriers in this sector, as these products require strict regulatory approvals and involve significant customer switching costs. Because these systems are perceived to deliver medicine more effectively than oral alternatives, Shaily management remains optimistic about long-term demand.
Capacity Expansion and New Markets
To support this growth, Shaily is rapidly expanding its production. The company produced approximately 24 million pens in fiscal year 2026 and aims to reach 36 million in fiscal year 2027, with a target of 50 million units by fiscal year 2028. Beyond this, a new facility in Abu Dhabi is expected to start commercial operations by fiscal year 2028, adding a potential capacity of 75 million pens. To reduce risk, the company has already secured customer commitments for roughly 60-65% of this future capacity.
Additionally, Shaily is entering the semiconductor packaging space. Through a partnership with a South Korean company, it plans to manufacture chip trays used in the assembly and packaging of semiconductors. Supplies to Indian firms are expected to begin by the fourth quarter of fiscal year 2027, marking a move to diversify beyond healthcare.
Financial Reality and Risks
While the growth narrative is strong, investors should consider the current valuation. The stock is trading at approximately 47 times its projected fiscal year 2028 earnings, which suggests the market has high expectations for future performance. This leaves little room for execution errors.
Performance in the fourth quarter of fiscal year 2026 also highlighted some vulnerabilities. While healthcare revenues surged by 163% year-over-year, the consumer segment saw a 31% decline, indicating uneven growth across different business lines. Furthermore, the company faces specific industry risks. The rise of oral GLP-1 alternatives could disrupt the market for pen injectors, and the business remains sensitive to customer-driven regulatory timelines for product approvals. The ongoing softness in consumer demand across Europe and the U.S. also remains a point to track.